EDITORIAL Adverse event reporting in oncology clinical trials - lost in translation?

Editorial

 ....The CONSORT harms extension statement represented
a move in the right direction toward standardization.
However, adherence to these guidelines has been variable
likely for multiple reasons including lack of knowledge regarding
the guidelines, lack of enforcement, and perhaps most
importantly, that the guidelines focus largely on transparency
of reporting rather than establishing standards to ensure consistency
of data presentation across trials. There is an urgent
need within the oncologic community for stakeholders to
develop a standard approach to the analysis, synthesis, and
reporting of clinical trial adverse event data.